Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

Abstract: The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

Abstract: A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.

Abstract: The invention provides antibodies that specifically bind to integrin ?v?6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ?v?6.

Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.

Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.

Abstract: The present invention relates to the use of type 1 interferon receptor antagonists that specifically bind IFNAR1 and/or IFNAR2 and inhibit type 1 IFNs signalling in methods of treating tuberculosis and other infectious diseases, in which type 1 interferon signalling has been found to be deleterious. Infectious diseases that can be treated according to the present invention include tuberculosis and leishmaniasis.

Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).

Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.

Abstract: The present invention provides antibodies that bind Glucocorticoid Induced Tumor necrosis factor Receptor family related protein (GITR) and methods of using same. The anti-GITR antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.

Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.

Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.

Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.

Abstract: There is provided a method for producing hypromellose phthalate (HPMCP), the method not requiring any special device, and facilitating removal of impurities. More specifically, there is provided a method for producing HPMCP, including an esterification step of esterifying hypromellose with a carboxybenzoylating agent in the presence of an aliphatic carboxylic acid to obtain a reaction product solution containing HPMCP; a precipitation step of precipitating the HPMCP by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCP; a neutralization step of neutralizing the suspension with a basic substance to obtain a neutralized suspension; and a washing step of washing the HPMCP contained in the neutralized suspension to obtain the washed HPMCP.

Abstract: There is provided a method for producing hypromellose acetate succinate (HPMCAS), the method not requiring any special device and facilitating removal of impurities. More specifically, there is provided a method for producing HPMCAS, including an esterification step of esterifying hypromellose with an acetylating agent and a succinoylating agent in the presence of an aliphatic carboxylic acid to obtain a reaction product solution containing HPMCAS; a precipitation step of precipitating the HPMCAS by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCAS; a neutralization step of neutralizing the suspension with a basic substance to obtain a neutralized suspension; and a washing step of washing the HPMCAS contained in the neutralized suspension to obtain the washed HPMCAS.

Abstract: A method of producing a carboxyl group-containing nitrile rubber including a coagulation step of coagulating a carboxyl group-containing nitrile rubber component by mixing a monovalent metal salt and a polymer flocculating agent into a carboxyl group-containing nitrile rubber latex having an iodine value of 120 or less, wherein the monovalent metal salt is compounded in an amount of 3 to 25 parts by weight and the polymer flocculating agent is compounded in an amount of 0.

Abstract: An aqueous polymer dispersion, a process of preparing the aqueous polymer dispersion, and an aqueous coating composition comprising the aqueous polymer dispersion and providing coatings with improved water repellency and/or improved hydrophobic stain resistance without compromising hydrophilic stain resistance.

Abstract: Process for the preparation of heterophasic propylene copolymer compositions (RAHECO) made from or containing a random propylene copolymer (RACO) and an elastomeric propylene copolymer (BIPO), the process being carried out in a reactor having two interconnected polymerization zones, a riser and a downcomer, wherein growing polymer particles: (a) flow through the first polymerization zone, the riser, under fast fluidization conditions in the presence of propylene and of ethylene or an alpha-olefin having from 4 to 10 carbon atoms, thereby obtaining the random propylene copolymer (RACO); (b) leave the riser and enter the second polymerization zone, the downcomer, through which the growing polymer particles flow downward in a densified form in the presence of propylene and of ethylene or an alpha-olefin having from 4 to 10 carbon atoms, wherein the concentration of ethylene or of the alpha-olefin in the downcomer is higher than in the riser, thereby obtaining the elastomeric propylene copolymer (BIPO); and (c)

Abstract: Embodiments of the present disclosure directed towards polymerization catalysts having improved ethylene enchainment. As an example, the present disclosure provides a polymerization catalyst having improved ethylene enchainment, the polymerization catalyst comprising a zirconocene catalyst of Formula (I) where R1 is a C1 to C20 alkyl, aryl or aralkyl group, wherein R2 is an C1 to C20 alkyl, aryl or aralkyl group, and where R3 is a C1 to C20 alkyl or a hydrogen, and where each X is independently a halide, C1 to C20 alkyl, aralkyl group or hydrogen.

Abstract: A rubbery polymer extrusion dryer includes a cylinder; and a die having a plurality of openings at one end of the cylinder, wherein each of the openings includes an opening base and at least one extended opening portion in communication with the opening base, and the extended opening portion has a shape with an opening width expanding in a direction away from the opening base.

Abstract: Embodiments are directed to phosphaguanidine metal complexes of formula I and using those complexes in ?-olefin polymerization systems.

Abstract: Novel stress-reducing crosslinking oligomers that have application in dental restoratives, thin films, hardcoats, composites, adhesives, and other uses subject to stress reduction are described. The addition-fragmentation process of crosslinking results in a chain-transfer event that provides novel polymers that may be further functionalized. In addition, the addition-fragmentation oligomer comprises pendent functional groups that bond to a substrate by forming an ionic or covalent bond, or etch the substrate by chemically removing some material from the substrate.

Abstract: A homopolypropylene has i) a molecular weight distribution of less than 2.4; ii) a melt index (measured at 230° C. under a load of 2.16 kg in accordance with ASTM D1238) of 5 to 3000 g/10 min; iii) a remaining stress ratio of 0.5% or less; and iv) a complex viscosity of 5 to 600 Pa·s at an angular frequency of 1 rad/s and a complex viscosity of 5 to 300 Pa·s at an angular frequency of 100 rad/s. A method for preparing the homopolyproylene is also provided. A molded article and a non-woven fabric are also provided.

Abstract: A sidewall support and/or a bead apex that is manufactured from a rubber composition that is based upon a cross-linkable rubber composition comprising a rubber component selected from the group consisting of a polybutadiene and at least one of a natural rubber and a polyisoprene. Such rubber compositions may further include a carbon black and also include a sulfur curing agent and a peroxide curing agent.

Abstract: A process including contacting one or more monomers, at least one catalyst system, and a condensing agent including a majority of propane under polymerizable conditions to produce a polyolefin polymer is provided.

Abstract: An object of the present invention is to provide a polyethylene-based resin composition excellent in the moldability and at the same time, excellent in the balance between impact strength and stiffness as well as in the transparency, and a molded product and a film, which are obtained by the molding of the polyethylene-based resin composition. The polyethylene-based resin composition of the present invention comprises from 41 to 99 wt % of (A) an ethylene-based polymer satisfying specific conditions and from 1 to 59 wt % of (B) an ethylene-based polymer satisfying specific conditions, wherein MFR of the composition as a whole is from 0.05 to 50 g/10 min and the density is from 0.910 to 0.960 g/cm3.

Abstract: A curable resin composition provides a cured resin product having excellent heat resistance and flame retardancy by curing. The curable resin composition includes a polyalkenyl phenol compound (A) and a polymaleimide compound (B), wherein the polyalkenyl phenol compound (A) is a compound containing at least two structural units represented by the following formula (1a): where R1 to R7 each independently represent a hydrogen atom, a C1-10 alkyl group, a C1-2 alkoxy group, a C2-6 alkenyl group, or a hydroxy group, Y1 is an alkenyl group.

Abstract: The invention aims to provide a polymer that can exhibit excellent calcium phosphate scale inhibition performance. The invention relates to a sulfuric acid (salt) ester group-containing copolymer containing a structural unit (a) derived from a sulfuric acid (salt) ester group-containing monomer (A) represented by the formula (1) and a structural unit (b) derived from an unsaturated carboxylic acid monomer (B).

Abstract: Copolymers and compositions containing copolymers having advantageous viscosity, friction reduction, dissolution, pH-stability, and temperature-stability are provided. These copolymers can be used as rheology modifiers for oil field applications.

Abstract: Provided is a composition including an acrylamide compound having a molecular weight of 150 or greater but 250 or less (A1), and a monomer having a cyclic structure represented by General Formula (3) below, or General Formula (4) below, or both (A2), where, in General Formulae (3) and (4), L is a single bond or a straight chain or branched alkylene group that has from 1 through 10 carbon atoms and may include an oxygen atom, a nitrogen atom, or a sulfur atom; A is a cyclic structure that has from 2 through 10 carbon atoms and may include an oxygen atom, a nitrogen atom, or a sulfur atom; R6 is a hydrogen atom or a methyl group; and R7 and R8 are each a straight chain or branched alkyl group having from 1 through 10 carbon atoms.

Abstract: Provided is a polymer composition that can be molded while having excellent resistance to wet heat whitening and suppressing yellowness. A polymer composition comprising: (A) a polymer comprising 0.01 mol % or more and 10 mol % or less of a ring structural unit with respect to a total of the ring structural unit and a monomer unit other than the ring structural unit; and (B) 0.1 ppm by mass or more and 2 ppm by mass or less of alkali metal and/or alkaline earth metal with respect to the whole polymer composition.

Abstract: Provided is a polymerizable composition that is capable of forming an optical film, etc. having excellent reverse wavelength dispersibility, can be prepared at relatively low temperature, and has excellent stability around room temperature.

Abstract: Disclosed herein are water-soluble polymers comprising hydrolyzable cross-linked monomer units, and methods for recovering hydrocarbon fluids from a subterranean formation using the water-soluble polymers.

Abstract: A curable resin composition, which has excellent flowability and reactivity at the time of molding, with which a highly reliable cured product which has excellent heat resistance can be obtained by curing is provided. A curable resin composition comprising a polyalkenyl phenol compound (A) and a polymaleimide compound (B), wherein the polyalkenyl phenol compound (A) is a compound containing at least two structural units represented by the following formula (1): where R1 and R2 each independently represent a hydrogen atom, a C1-10 alkyl group, a C1-2 alkoxy group, or a hydroxy group, Q represents a C5-10 cycloalkylene group or a divalent organic group containing an alicyclic fused ring, and Y is an alkenyl group.

Abstract: Metallic complexes having indenyl ligands can be used as an ingredient of a catalyst system. The catalyst system can be used in polymerizations of ethylenically unsaturated hydrocarbon monomers that include both olefins and polyenes. Embodiments of the catalyst system can provide interpolymers that include polyene mer and from 40 to 75 mole percent ethylene mer, with a plurality of the ethylene mer being randomly distributed. The catalyst system also can be used in solution polymerizations conducted in C5-C12 alkanes, yielding interpolymers that include at least 10 mole percent ethylene mer.

Abstract: A modified conjugated diene-based polymer having a weight average molecular weight of 20×104 or more and 300×104 or less, and having a molecular weight distribution Mw/Mn of 1.6 or more and 4.0 or less, wherein a modification ratio with respect to a total amount of the conjugated diene-based polymer is 50% by mass or more, a modification ratio of a component having a molecular weight which is ½ of a molecular weight at a peak top, or a peak top of the minimum molecular weight when a plurality of the peak tops of molecular weights is present, in a gel permeation chromatography curve is ½ or more of the modification ratio with respect to the total amount of the conjugated diene-based polymer, and a content of nitrogen contained in the modified conjugated diene-based polymer is 3 mass ppm or more and 70 mass ppm or less.

Abstract: The method for producing a conjugated diene-based polymer of the invention comprises step 1 in which a polymerization initiator is added to a monomer including a conjugated diene compound in a hydrocarbon solvent to obtain a polymerization solution, and step 2 in which a polymerization initiator is further added to the polymerization solution either once or two or more times to obtain a polymer with an active end, wherein in step 1 and/or step 2, a modifying agent is added which has a functional group that is copolymerizable with the conjugated diene compound.

Abstract: A method to produce a polymer gel includes dissolving precursors in a solvent to form a precursor solution, the precursors including polymer precursors, a stable free radical, one or more initiating radicals, and one or more stable free radical control agents, and heating the precursor solution to a temperature of polymerization to produce a cross-linked gel. A dried polymer aerogel has a Brunauer-Emmett Teller (BET) surface area over 100 m2/g, porosity of greater than 10%, visible transparency greater than 20%, color rendering index of over 20%, and average pore size of less than 100 nm.

Abstract: The present invention relates to a polyolefin-polystyrene multi-block copolymer having a structure comprising a polyolefin block and polystyrene blocks bonded to both ends of the polyolefin block, to an organozinc compound for preparing the same, and a method for preparing the polyolefin-polystyrene multi-block copolymer.

Abstract: Disclosed herein is a coupled polymer product comprising polymer with up to four polymer chains bonded to a functionalizing compound of formula II, wherein the polymer chains are comprised of conjugated diene-containing monomers optionally in combination with vinyl aromatic monomers and further include vinyl group-functionalized silane compound of formula I bonded within the polymer chain. Also disclosed are processes for producing the coupled polymer product as well as a rubber composition containing the coupled polymer product and tire components comprising the rubber composition.

Abstract: A rubber composition comprises at least one resin based on: (A1) at least one aromatic compound resulting from the reaction between a reactant of formula (?): where B represents CHO or CH2OH, (?) and a reactant of formula (?) or and (A2) at least one phenolic compound chosen from: (A21) at least one aromatic polyphenol comprising at least one aromatic ring bearing at least two hydroxyl functional groups in the meta position with respect to one another, the two positions ortho to at least one of the hydroxyl functional groups being unsubstituted; and/or (A22) at least one aromatic monophenol comprising at least one six-membered aromatic ring bearing a single hydroxyl functional group, the two positions ortho to the hydroxyl functional group being unsubstituted or at least one position ortho to and the position para to the hydroxyl functional group being unsubstituted.

Abstract: Embodiments of the present disclosure are directed towards polyol compositions including a dispersion of polyisocyanate polyaddition particles in a carrier polyol, wherein the polyisocyanate polyaddition particles have an average particle diameter from 0.1 to 10.0 microns and the dispersion has a solids content from 5 wt % to 50 wt % based upon a total weight of the dispersion, and a polyester polyol that is from 1 wt % to 98 wt % of the polyol composition based upon a total weight of the polyol composition.

Abstract: Clearcoat compositions and methods for forming a clearcoat compositions are provided. In one example, a clearcoat composition includes a binder portion A that includes a polyaspartic ester resin. An activator portion B includes a polyol-modified isocyanate that is a reaction product of a polyisocyanate component and a polyol component. The polyol component includes polycaprolactone polyol.

Abstract: Polyurethane foams are made by curing a reaction mixture that contains an aromatic polyisocyanate, at least one isocyanate-reactive material having an average functionality of at least 2 and an equivalent weight of at least 200 per isocyanate-reactive group, at least one blowing agent, at least one surfactant and at least one catalyst, at least one cyclic 1,3-diketone compound and optionally least one antioxidant. Foams so produced emit low levels of both formaldehyde and acetaldehyde.